Femilyane Menalya Ménopause
Food supplement declared in France, declaration No 2023-8-1321, decision dated 25 August 2023
Femilyane Menalya Ménopause, from Laboratoires Bailleul S.A., is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Linum usitatissimum 75 mg per day, Humulus lupulus 30 mg per day, Pantothenic acid (vitamin B5), Iron, Folate (vitamin B9). 1 rule of use applies to its ingredients (limits and warnings).
- Brand
- Femilyane
- Food business operator placing the product on the market
- Laboratoires Bailleul S.A.
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Autre : gélules et capsules
- Daily dose
- 1 gélule + 1 capsule molle
- Directions for use
- 1 gélule par jour le matin et 1 capsule molle par jour le soir après le repas
- Intended populations
- Women
- Not recommended (according to the manufacturer)
- Adolescents (under 18), History of breast cancer, Children (under 12), Young children (aged 1 to 3), Infants (under 1 year), Children (under 6), Children (under 10)
- Objectives stated by the manufacturer (these are not authorised claims)
- Menopause
Declaration 187004, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Linum usitatissimum L. | Graine | Extrait sec hydroalcoolique | 75 mg |
| Humulus lupulus L. | Cône | Poudre (de plantes séchées ou broyées) | 30 mg |
Other active ingredients
| Name | Per day |
|---|---|
| Hydrolysat enzymatique de protéines de riz | not declared |
| Huile de Krill | not declared |
| huile de calanus | not declared |
| Huile de poisson | not declared |
Vitamins and minerals
Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).
| Declared form | Nutrient | EFSA limit, adults | Maximum dose in France |
|---|---|---|---|
| D-pantothenate, calcium | Pantothenic acid (vitamin B5) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| ferrous sulphate | Iron | 40 mg (safe level) | 14 mg |
| pteroylmonoglutamic acid | Folate (vitamin B9) | 1,000 µg | 200 µg |
| magnesium oxide | Magnesium | 250 mg | 300 mg |
| nicotinamide | Nicotinamide (vitamin B3) | 900 mg | 54 mg |
| thiamin mononitrate | Vitamin B1 (thiamine) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| cyanocobalamin | Vitamin B12 | no adverse effect defined | dose annulled by the French Council of State in 2011 |
| riboflavin | Vitamin B2 (riboflavin) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| pyridoxine hydrochloride | Vitamin B6 | 12 mg | 2 mg |
| L-ascorbic acid | Vitamin C | no limit (insufficient data) | 180 mg |
| cholecalciferol | Vitamin D | 100 µg (4,000 IU) | 5 µg (200 IU) |
| D-alpha-tocopheryl acid succinate | Vitamin E | 300 mg | 30 mg |
| zinc sulphate | Zinc | 25 mg | 15 mg |
Additives
E470b, E464
Other ingredients
amidon de maïs, Gélatine de poisson
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Label warnings
Conserver à l’abri de la chaleur (15-25°C), de l’humidité et de la lumière dans son emballage d’origine fermé. Ne pas dépasser la dose journalière recommandée. Les compléments alimentaires ne se substituent pas à une alimentation variée et équilibrée ni à un mode de vie sain. Tenir hors de la portée des jeunes enfants. Déconseillé aux femmes ayant des antécédents personnels ou familiaux de cancer du sein. Réservé à l’adulte. Ne doit pas être consommé si d’autres compléments alimentaires contenant des esters d’astaxanthine sont consommés le même jour.
Regulatory points
- Conditions légales
Linum usitatissimum L.: L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Linum usitatissimum L.
Read the warning, when it applies and the studies cited
FLAXSEED - LINUM USITATISSIMUM
Route of administration: Oral
Cautions and warnings
Applies to products providing 5 g or more of flaxseed per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician immediately if you experience chest pain, vomiting, or difficulty swallowing or breathing after taking this product (EMA 2015).
Sources cited by Health Canada (1)
- EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes or a lazy bowel (EMA 2015; ESCOP 2003).
Sources cited by Health Canada (2)
- EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
Condition of application: Laxative; Promotion of bowel movement; Constipation.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or if laxative effect does not occur within 7 days (Pray 2006; Repchinsky 2002).
Sources cited by Health Canada (2)
- Pray WS. 2006. Non-Prescription Product Therapeutics, 2nd edition. New York (NY): Lippincott Williams & Wilkins.
- Repchinsky 2002: Canadian Pharmacists Association. Patient Self-Care. Helping Patients Make Therapeutic Choices. Ottawa (ON): Canadian Pharmacists Association.
Contraindications
Applies to products providing 5 g or more of flaxseed per day.
Do not use if you have difficulty swallowing (EMA 2015; ESCOP 2003).
Sources cited by Health Canada (2)
- EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
Do not use if you have fever or any undiagnosed gastrointestinal trouble (EMA 2015; Gardner and McGuffin 2013; Brinker 2010; ESCOP 2003).
Sources cited by Health Canada (4)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
- Gardner Z. and McGuffin M. editors. American Herbal Products Association's Botanical Safety Handbook, 2nd edition. American Herbal Products Association. Boca Raton (FL): CRC Press; 2013.
Known adverse reactions
Condition of application: All products.
Stop use if hypersensitivity/allergy occurs (EMA 2015; León et al. 2003).
Sources cited by Health Canada (2)
- EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf
- León F, Rodríguez M, Cuevas M. 2003. Anaphylaxis to Linum. Allergologia et immunopathologia 31(1):47-49.
- Humulus lupulus L.
Read the warning, when it applies and the studies cited
HOPS - HUMULUS LUPULUS
Route of administration: Oral
Cautions and warnings
Condition of application: Sleep aid.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists continuously for more than 4 weeks (chronic insomnia) (Berardi et al. 2002; Dipiro et al. 2002).
Sources cited by Health Canada (2)
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
- Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: a pathophysiologic approach, 5th edition. New York (NY): The McGraw-Hill Companies, Inc.; 2002.
Condition of application: Other uses.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Brinker 2010; Barnes et al. 2007; Mills and Bone 2005; McGuffin et al. 1997).
Sources cited by Health Canada (4)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
- Brinker F. Herb Contraindications and Drug interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
- McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.
When using this product avoid taking with alcohol or products that cause drowsiness (Brinker 2010).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2014 : European Medicines Agency. Draft Community Herbal Monograph on Humulus lupulus L., Flos. London (UK): EMEA Committee on Herbal Medicinal Products (HMPC), 6 Mai 2014. [Consulté le 14 septembre 2023]. Disponible à : https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-humulus-lupulus-l-flos-revision-1_en.pdf
When using this product exercise caution if you drive or use machinery as this product may cause drowsiness (EMA 2014).
Sources cited by Health Canada (5)
- EMA 2014: European Medicines Agency. Draft Community Herbal Monograph on Humulus lupulus L., Flos. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 6 May 2014. [Accessed 2023 September 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-humulus-lupulus-l-flos-revision-1_en.pdf
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3e édition. London (UK): The Pharmaceutical Press; 2007.
- Brinker F. Herb Contraindications and Drug interactions, 4e édition. Sandy (OR): Eclectic Medical Publications; 2010.
- McGuffin M, Hobbs C, Upton R, Goldberg A, éditeurs. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.
- Huile de Krill
Read the warning, when it applies and the studies cited
Krill Oil
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (HC 2009).
Sources cited by Health Canada (2)
- HC 2009: Health Canada, It's your health. Food Allergies. Ottawa (ON): Health Canada. [Original: June 2009; Accessed 2024 November 20]. Available from: https://www.hc-sc.gc.ca/hl-vs/alt_formats/pacrb-dgapcr/pdf/iyh-vsv/food-aliment/allerg-eng.pdf
- SC 2009: Santé Canada, Votre santé et vous. Allergies alimentaires. Ottawa (ON) : Santé Canada. [Original: Juin 2009; Consulté le 20 novembre 2024] Disponible à : https://www.hc-sc.gc.ca/hl-vs/alt_formats/pacrb-dgapcr/pdf/iyh-vsv/food-aliment/allerg-fra.pdf
- Huile de poisson
Read the warning, when it applies and the studies cited
FISH OIL
Route of administration: Oral
Cautions and warnings
Condition of application: Pain of rheumatoid arthritis.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.
Condition of application: Healthy mood balance.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have psychological disorders such as anxiety or depression.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Other declarations with the same name
In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.
- Femilyane Menalya Ménopause Femilyane, declared in 2026 : different composition: 0 ingredient(s) added, 1 missing
Brand : Femilyane
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Femilyane Menalya Ménopause: composition and regulation”, https://compoatlas.com/en/supplements/products/187004-femilyane-menalya-menopause, updated 15 November 2026.